bluebird bio (BLUE) Rating Reiterated by Cantor Fitzgerald

Share on StockTwits

Cantor Fitzgerald reiterated their hold rating on shares of bluebird bio (NASDAQ:BLUE) in a report published on Monday. They currently have a $134.00 price target on the biotechnology company’s stock.

“We rate bluebird bio Neutral. BLUE, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for rare severe genetic diseases. Its product candidates include Lenti-D, which is in a pivotal clinical study for the treatment of cerebral adrenoleukodystrophy; LentiGlobin, which is in Phase 1/2 clinical studies for the treatment of beta thalassemia major and severe sickle cell disease (SCD); and bb2121 and bb21217 CAR-T, candidates in multiple myeloma. Valuation Summary We value bluebird bio based on a risk-adjusted NPV calculation of its clinical pipeline.”,” the firm’s analyst wrote.

A number of other analysts also recently issued reports on the stock. Morgan Stanley reduced their price target on shares of bluebird bio from $190.00 to $186.00 and set an equal weight rating on the stock in a report on Monday, October 15th. ValuEngine upgraded shares of bluebird bio from a buy rating to a strong-buy rating in a report on Tuesday, October 2nd. BidaskClub downgraded shares of bluebird bio from a sell rating to a strong sell rating in a report on Tuesday, October 23rd. Goldman Sachs Group downgraded shares of bluebird bio from a conviction-buy rating to a buy rating in a report on Friday, September 21st. Finally, Sanford C. Bernstein upgraded shares of bluebird bio from a market perform rating to an outperform rating and set a $155.00 price target on the stock in a report on Wednesday, November 14th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and seventeen have issued a buy rating to the stock. bluebird bio currently has an average rating of Buy and an average target price of $194.80.

Shares of NASDAQ BLUE opened at $108.85 on Monday. The firm has a market capitalization of $6.22 billion, a price-to-earnings ratio of -14.12 and a beta of 2.37. bluebird bio has a 52-week low of $100.99 and a 52-week high of $236.17.

bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings results on Thursday, November 1st. The biotechnology company reported ($2.73) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.90) by $0.17. The company had revenue of $11.50 million for the quarter, compared to the consensus estimate of $6.90 million. bluebird bio had a negative net margin of 1,326.02% and a negative return on equity of 31.50%. bluebird bio’s revenue for the quarter was up 49.2% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.73) EPS. On average, equities research analysts predict that bluebird bio will post -10.71 earnings per share for the current year.

In related news, insider David Davidson sold 2,000 shares of bluebird bio stock in a transaction dated Tuesday, December 4th. The shares were sold at an average price of $121.05, for a total transaction of $242,100.00. Following the completion of the transaction, the insider now directly owns 30,905 shares of the company’s stock, valued at approximately $3,741,050.25. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Susanna Gatti High sold 1,890 shares of bluebird bio stock in a transaction dated Monday, December 3rd. The stock was sold at an average price of $113.83, for a total transaction of $215,138.70. Following the transaction, the chief operating officer now directly owns 15,610 shares of the company’s stock, valued at $1,776,886.30. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 21,490 shares of company stock worth $2,901,186. Insiders own 3.00% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the stock. CIBC Asset Management Inc boosted its stake in shares of bluebird bio by 28.5% during the 2nd quarter. CIBC Asset Management Inc now owns 1,780 shares of the biotechnology company’s stock worth $279,000 after purchasing an additional 395 shares during the period. State of Alaska Department of Revenue boosted its stake in shares of bluebird bio by 9.2% during the 3rd quarter. State of Alaska Department of Revenue now owns 6,320 shares of the biotechnology company’s stock worth $922,000 after purchasing an additional 530 shares during the period. Dynamic Technology Lab Private Ltd boosted its stake in shares of bluebird bio by 43.2% during the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 2,040 shares of the biotechnology company’s stock worth $320,000 after purchasing an additional 615 shares during the period. Aperio Group LLC boosted its stake in shares of bluebird bio by 9.7% during the 2nd quarter. Aperio Group LLC now owns 7,295 shares of the biotechnology company’s stock worth $1,145,000 after purchasing an additional 646 shares during the period. Finally, Stratos Wealth Partners LTD. purchased a new position in shares of bluebird bio during the 3rd quarter worth about $106,000.

About bluebird bio

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.

Featured Article: How is a Moving Average Calculated?

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

PRiVCY  Reaches Market Capitalization of $60,608.00
PRiVCY Reaches Market Capitalization of $60,608.00
DaxxCoin   Trading 1.9% Lower  This Week
DaxxCoin Trading 1.9% Lower This Week
CymaBay Therapeutics Inc  Receives Average Recommendation of “Buy” from Brokerages
CymaBay Therapeutics Inc Receives Average Recommendation of “Buy” from Brokerages
Capital City Bank Group, Inc.  Given Consensus Rating of “Hold” by Brokerages
Capital City Bank Group, Inc. Given Consensus Rating of “Hold” by Brokerages
AI Doctor  Trading 17.9% Lower  Over Last Week
AI Doctor Trading 17.9% Lower Over Last Week
Brokerages Set Farmers National Banc Corp  PT at $16.67
Brokerages Set Farmers National Banc Corp PT at $16.67


Leave a Reply

 
© 2006-2018 Zolmax.